These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26620151)

  • 1. Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor.
    Lazaar AL; Yang L; Boardley RL; Goyal NS; Robertson J; Baldwin SJ; Newby DE; Wilkinson IB; Tal-Singer R; Mayer RJ; Cheriyan J
    Br J Clin Pharmacol; 2016 May; 81(5):971-9. PubMed ID: 26620151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.
    Yang L; Cheriyan J; Gutterman DD; Mayer RJ; Ament Z; Griffin JL; Lazaar AL; Newby DE; Tal-Singer R; Wilkinson IB
    Chest; 2017 Mar; 151(3):555-563. PubMed ID: 27884766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans.
    Luther JM; Ray J; Wei D; Koethe JR; Hannah L; DeMatteo A; Manning R; Terker AS; Peng D; Nian H; Yu C; Mashayekhi M; Gamboa J; Brown NJ
    Hypertension; 2021 Sep; 78(4):1092-1102. PubMed ID: 34455816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage.
    Martini RP; Siler D; Cetas J; Alkayed NJ; Allen E; Treggiari MM
    Neurocrit Care; 2022 Jun; 36(3):905-915. PubMed ID: 34873674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice.
    Morgan LA; Olzinski AR; Upson JJ; Zhao S; Wang T; Eisennagel SH; Hoang B; Tunstead JR; Marino JP; Willette RN; Jucker BM; Behm DJ
    J Cardiovasc Pharmacol; 2013 Apr; 61(4):291-301. PubMed ID: 23232840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells.
    Mashayekhi M; Wanjalla CN; Warren CM; Simmons JD; Ghoshal K; Pilkinton M; Bailin SS; Gabriel CL; Pozzi A; Koethe JR; Brown NJ; Kalams SA; Luther JM
    Prostaglandins Other Lipid Mediat; 2022 Feb; 158():106604. PubMed ID: 34922004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor.
    Podolin PL; Bolognese BJ; Foley JF; Long E; Peck B; Umbrecht S; Zhang X; Zhu P; Schwartz B; Xie W; Quinn C; Qi H; Sweitzer S; Chen S; Galop M; Ding Y; Belyanskaya SL; Israel DI; Morgan BA; Behm DJ; Marino JP; Kurali E; Barnette MS; Mayer RJ; Booth-Genthe CL; Callahan JF
    Prostaglandins Other Lipid Mediat; 2013; 104-105():25-31. PubMed ID: 23434473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of soluble epoxide hydrolase inhibitors through DNA-encoded library technology (ELT).
    Ding Y; Belyanskaya S; DeLorey JL; Messer JA; Joseph Franklin G; Centrella PA; Morgan BA; Clark MA; Skinner SR; Dodson JW; Li P; Marino JP; Israel DI
    Bioorg Med Chem; 2021 Jul; 41():116216. PubMed ID: 34023664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovering Drugs with DNA-Encoded Library Technology: From Concept to Clinic with an Inhibitor of Soluble Epoxide Hydrolase.
    Belyanskaya SL; Ding Y; Callahan JF; Lazaar AL; Israel DI
    Chembiochem; 2017 May; 18(9):837-842. PubMed ID: 28281333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
    Revermann M
    Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.
    Reisdorf WC; Xie Q; Zeng X; Xie W; Rajpal N; Hoang B; Burgert ME; Kumar V; Hurle MR; Rajpal DK; O'Donnell S; MacDonald TT; Vossenkämper A; Wang L; Reilly M; Votta BJ; Sanchez Y; Agarwal P
    PLoS One; 2019; 14(4):e0215033. PubMed ID: 31002701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects.
    Chen D; Whitcomb R; MacIntyre E; Tran V; Do ZN; Sabry J; Patel DV; Anandan SK; Gless R; Webb HK
    J Clin Pharmacol; 2012 Mar; 52(3):319-28. PubMed ID: 21422238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.
    Pallàs M; Vázquez S; Sanfeliu C; Galdeano C; Griñán-Ferré C
    Biomolecules; 2020 May; 10(5):. PubMed ID: 32369955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model.
    Chen L; Fan C; Zhang Y; Bakri M; Dong H; Morisseau C; Maddipati KR; Luo P; Wang CY; Hammock BD; Wang MH
    Prostaglandins Other Lipid Mediat; 2013; 104-105():42-8. PubMed ID: 23247129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an online SPE-LC-MS-based assay using endogenous substrate for investigation of soluble epoxide hydrolase (sEH) inhibitors.
    Schebb NH; Huby M; Morisseau C; Hwang SH; Hammock BD
    Anal Bioanal Chem; 2011 May; 400(5):1359-66. PubMed ID: 21479549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
    Motoki A; Merkel MJ; Packwood WH; Cao Z; Liu L; Iliff J; Alkayed NJ; Van Winkle DM
    Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2128-34. PubMed ID: 18835921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.
    Revermann M; Barbosa-Sicard E; Dony E; Schermuly RT; Morisseau C; Geisslinger G; Fleming I; Hammock BD; Brandes RP
    J Hypertens; 2009 Feb; 27(2):322-31. PubMed ID: 19226702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.
    Roche C; Besnier M; Cassel R; Harouki N; Coquerel D; Guerrot D; Nicol L; Loizon E; Remy-Jouet I; Morisseau C; Mulder P; Ouvrard-Pascaud A; Madec AM; Richard V; Bellien J
    Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1020-9. PubMed ID: 25724490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo.
    Zhang D; Xie X; Chen Y; Hammock BD; Kong W; Zhu Y
    Circ Res; 2012 Mar; 110(6):808-17. PubMed ID: 22354938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.